Venue: Edificio Povo 2, via Sommarive nr. 9, Povo (Tn) - Room B104
At 4:00 p.m.
- Antonio Musarò - Unit of Histology and Medical Embryology, Sapienza University of Rome, Italy
The prolongation of skeletal muscle strength in neuromuscular diseases, including muscular dystrophy, has been the objective of numerous studies employing a variety of approaches. Stem cell therapy represents a promising tool. However, this approach is not definitive yet and several hurdles limit the immediate translation of this strategy into clinic. One of the crucial parameters is the microenvironment in which the stem cell populations should operate. Among critical parameters, the activation and persistence of inflammatory pathways, associated with several neuromuscular diseases, may render the muscle incapable to sustain and complete an efficient muscle regeneration. The anti-inflammatory agents glucocorticoids (GC) are the only available treatment for certain genetic diseases, including Duchenne muscular dystrophy (DMD). However, long-term GC treatment causes muscle atrophy and wasting. Thus, targeting specific mediator of inflammatory response may be more specific, more efficacious, and with fewer side effects. In this presentation the role of the pro-inflammatory cytokines in the pathogenesis of Duchenne Muscular Dystrophy (DMD) and muscle regeneration will be discussed.